TRC

TRC TRC has over 40 years specialised in the production of quality products for innovative research.

💊GLP-1 agonist-based therapies have taken the world by storm in 2026.As weight loss treatments, they're already achievin...
09/02/2026

💊GLP-1 agonist-based therapies have taken the world by storm in 2026.
As weight loss treatments, they're already achieving remarkable sales in developed countries - while new dosage forms are expected to accelerate demand all around the world.

👩‍🔬Even more exciting, GLP-1s are showing promise for tackling a wide range of other ailments - including cancer, addiction, Alzheimer's, heart attacks, strokes, kidney disease, and more.

👇Our focused selection of GLP-1 research compounds is now available to support your method development, assay optimisation, and reference testing needs. It features:

✅semaglutide,
✅liraglutide,
✅exenatide acetate,
✅exenatide d5 acetate,
✅lixisenatide acetate, and
✅tirzepatide.

⬇️Explore the range: https://ow.ly/39Xo50ZGs2J

08/27/2026

Have you seen divergence between regulatory agencies on how they interpret acceptable impurity limits? 💬

In this clip from our expert panel discussion, Jörg Schlingemann, nitrosamine expert and consultant, discusses a recent example highlighting how regulatory expectations can vary between regions.

Drawing on a discussion with the Thai FDA, he explores how different interpretations of maximum daily dose can influence acceptable intake calculations for nitrosamines, creating challenges for companies preparing global submissions.

🎥 Want to hear more?
This on-demand panel discussion brings together five leading experts from industry, academia and regulatory science to explore the science, regulation and practical management of nitrosamines.

Register to watch on demand: 🔗 https://ow.ly/9NV650ZEOIt

08/20/2026

Where do ICH M7, FDA and EMA expectations stand today, and where are the remaining grey areas? 💬

In this clip from our expert panel discussion, Dr George Johnson, Associate Professor at Swansea University discusses one of the key challenges facing the pharmaceutical industry: the gap that can exist between scientific consensus and regulatory acceptance while guidance continues to evolve.

🎥 Want to hear more?
This on-demand panel discussion brings together five leading experts from industry, academia and regulatory science to explore the science, regulation and practical management of nitrosamines.

Register to watch on demand: 🔗 https://ow.ly/Jgh650ZBSOo

Can we predict the safety of extractables and leachables before testing every compound?📜 A new collaborative study invol...
08/18/2026

Can we predict the safety of extractables and leachables before testing every compound?

📜 A new collaborative study involving scientists from the FDA has analysed the chemical space of more than 1,200 pharmaceutical extractables and leachables, providing one of the most comprehensive overviews of these compounds to date. ( https://ow.ly/CIPf50ZAY0J )

💡The significance isn't simply the size of the dataset. By grouping structurally similar compounds and examining existing toxicity data, the work provides a stronger scientific foundation for read-across, helping toxicologists assess the safety of previously uncharacterised leachables more efficiently and consistently.

As extractables and leachables guidance continues to evolve, this type of evidence-based approach has the potential to make risk assessments more efficient while maintaining confidence in patient safety.

At LGC Standards, we support extractables and leachables workflows with a comprehensive portfolio of analytical reference standards for method development, identification and quantification. Explore the range: https://ow.ly/5a8w50ZAY0K

👋Calling all researchers: we want to hear your ideas about tackling emerging contaminants! Whether they’re PFAS or PCBs,...
08/14/2026

👋Calling all researchers: we want to hear your ideas about tackling emerging contaminants!

Whether they’re PFAS or PCBs, microplastics or flame retardants, we’re interested in innovative ways of dealing with them – from detection and monitoring to risk assessment and mitigation.

📨Enter our poster competition by submitting an abstract of up to 200 words, explaining how your ideas can help defend our water, soil, air and food chain.

All abstracts will then be reviewed by an expert panel, and shortlisted entries presented at a virtual webinar next year.

🏆Prizes include up to £2,000 worth of reference standards to support future research, and Amazon eGift cards worth up to £200 for the winner.

Deadline: October 14, 2026.

✍️Sign up for the competition: https://ow.ly/NfYc50ZyQcQ

Many factors influence the reported API potency result.From sample preparation and reference standards to instrument per...
08/13/2026

Many factors influence the reported API potency result.

From sample preparation and reference standards to instrument performance and method validation, every stage of the assay can affect the final result. Understanding these sources of variation is essential for generating accurate and reliable potency data.

💡Our latest application note explores sources of systematic bias in LC–UV potency assays and practical strategies to minimise them.

⬇️ Download the application note: https://ow.ly/EvhX50ZxGO6

08/11/2026

Our quality reference standards can help your lab to meet strict regulatory limits on NDSRIs and small molecule nitrosamines around the world.

We offer:
✔️650+ NDSRI compounds for major therapeutic areas (e.g. neuroscience, oncology, metabolic disorders),
✔️90+ small molecule nitrosamine reference materials (including NDMA, NDEA, NMBA and DIPNA),
✔️Active development pipelines (150+ NDSRIs in progress and new products released monthly),
✔️Rapid, responsive custom synthesis,
✔️Varied formats, including neats, ready-to-use solutions, plus native and labelled standards,
✔️Multiple quality levels to suit the nature of your work.

Discover more: https://ow.ly/VhSI50ZxHAW

08/05/2026

⚠️In nitrosamine analysis, matrix interference can obscure out-of-specification results, risking the release of noncompliant batches.

Our free webinar - “Trace-Level Quantification of Nitrosamines in Pharmaceuticals: Pitfalls and Solutions” - features an essential case study on how to overcome such matrix effects.

By watching, you can learn more about relevant practical strategies, including:

✅use of internal stable isotope labelled standards,
✅modification of chromatography conditions and sample dilution to reduce matrix load
✅different calibration approaches, including external calibration and standard addition.

Watch now: https://ow.ly/yxAb50Zv3Nc

08/04/2026

Despite being at the top of the pharmaceutical agenda, there are still plenty of unresolved questions about how we control nitrosamines.

💡Our free webinar - featuring five experts from industry, academia and regulatory science - is an essential guide to the science, regulation and practical management of nitrosamines.

The discussion covers:

✔️how risk assessment and toxicology inform nitrosamine control and regulatory decisions,
✔️why changes to ICH M7 may affect the product lifecycle, and
✔️how method development, validation and standards underpin testing confidence.

Watch the panel discussion on demand now: https://ow.ly/Q3Z050Zv7VF

What you separate determines what you measure.💡 Our newest application note highlights practical strategies for improvin...
07/30/2026

What you separate determines what you measure.

💡 Our newest application note highlights practical strategies for improving method performance and generating more reliable potency measurements.

➡️ Swipe through for key insights and download the full application note here: https://ow.ly/kHno50Zu82C

Address

20 Martin Ross Avenue
Toronto, ON
M3J2K8

Website

Alerts

Be the first to know and let us send you an email when TRC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Category